Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells
- PMID: 688275
Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells
Abstract
The in vivo effects of VM-26 and VP-16-213 upon hematopoietic stem cells and L1210 leukemia cells were quantitated using the spleen-colony assay technique. The effect of VM-26 on leukemia cells was further quantitated using an endpoint dilution assay. The dose-response curves for leukemic clonogenic cells for both agents when given by iv injection were exponential and biphasic, indicating the existence of two populations. The survival of leukemia cells when VM-26 was administered as a 24-hour infusion was less than that found for equivalent doses administered as single injections. The survival kinetics with respect to time for a low dose (0.02 mg/mouse) and a high dose (0.15 mg/mouse) of VM-26 were similar in that the decrease in survival was rapid, reaching a maximum effect within 4 hours after administration. With the low dose, repopulation of the femoral marrow started immediately, whereas with the high dose, there was a 20-hour delay in repopulation. The data from the increase in lifespan studies were in excellent agreement with the quantitative assays. The dose-response curves for the normal hematopoietic clonogenic cells were also exponential, but these cells were much less sensitive to the agents than were the leukemia cells.
Similar articles
-
Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.Cancer Res. 1975 Aug;35(8):1926-30. Cancer Res. 1975. PMID: 50128
-
Comparison of cytotoxic action of iphosphamide and cyclophosphamide.Anticancer Res. 1981;1(3):149-54. Anticancer Res. 1981. PMID: 7342853
-
Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.NCI Monogr. 1987;(4):117-21. NCI Monogr. 1987. PMID: 3041238
-
Podophyllotoxin derivatives VP-16 and VM-26.Cancer Chemother Biol Response Modif. 1987;9:67-70. Cancer Chemother Biol Response Modif. 1987. PMID: 3079416 Review. No abstract available.
-
Podophyllotoxin derivatives VP-16 and VM-26.Cancer Chemother Biol Response Modif. 1988;10:57-63. Cancer Chemother Biol Response Modif. 1988. PMID: 3079398 Review. No abstract available.
Cited by
-
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.Cancer Chemother Pharmacol. 1990;27(3):194-8. doi: 10.1007/BF00685712. Cancer Chemother Pharmacol. 1990. PMID: 2265455
-
Podophyllotoxin derivative VP 16-213.Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976. Cancer Chemother Pharmacol. 1979. PMID: 389478 Review.
-
Multicompartment models of cancer chemotherapy incorporating resistant cell populations.J Pharmacokinet Biopharm. 1987 Apr;15(2):145-77. doi: 10.1007/BF01062341. J Pharmacokinet Biopharm. 1987. PMID: 3612499
-
A structure-activity relationship study of batracylin analogues.Pharm Res. 1993 Jun;10(6):918-23. doi: 10.1023/a:1018929815422. Pharm Res. 1993. PMID: 8391697
-
Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias.Cancer Chemother Pharmacol. 1986;18(2):101-4. doi: 10.1007/BF00262276. Cancer Chemother Pharmacol. 1986. PMID: 3791555